Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0R9HI
|
|||
Former ID |
DCL000391
|
|||
Drug Name |
SB-742457
|
|||
Synonyms |
GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [1] | |
Company |
GlaxoSmithKline
|
|||
Structure |
Download2D MOL |
|||
Formula |
C19H19N3O2S
|
|||
Canonical SMILES |
C1CN(CCN1)C2=CC=CC3=CC(=CN=C32)S(=O)(=O)C4=CC=CC=C4
|
|||
InChI |
1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2
|
|||
InChIKey |
JJZFWROHYSMCMU-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 607742-69-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
16342129, 23432880, 42336247, 57304406, 80580213, 103756096, 104152994, 125646223, 126671677, 131320697, 135261679, 137099831, 141802492, 162009827, 162210546, 162223698, 162567130, 163620787, 163686112, 174529998, 174538911, 186014821, 187072839, 188932818, 196409663, 198952878, 218903267, 223675869, 223947486, 227869399, 242059992, 245722800, 251910589, 251963241, 251971156, 252450570
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | 5-HT 6 receptor (HTR6) | Target Info | Antagonist | [2], [3] |
KEGG Pathway | Calcium signaling pathway | |||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Serotonergic synapse | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Pathwhiz Pathway | Excitatory Neural Signalling Through 5-HTR 6 and Serotonin | |||
Reactome | Serotonin receptors | |||
G alpha (s) signalling events | ||||
WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15. | |||
REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.